| __timestamp | Amphastar Pharmaceuticals, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 7890000 |
| Thursday, January 1, 2015 | 46974000 | 14456000 |
| Friday, January 1, 2016 | 47298000 | 19218000 |
| Sunday, January 1, 2017 | 50918000 | 27986000 |
| Monday, January 1, 2018 | 58044000 | 47928000 |
| Tuesday, January 1, 2019 | 63109000 | 96388000 |
| Wednesday, January 1, 2020 | 65157000 | 157743000 |
| Friday, January 1, 2021 | 68920000 | 195293000 |
| Saturday, January 1, 2022 | 66592000 | 237374000 |
| Sunday, January 1, 2023 | 80393000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
Cracking the code
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Amphastar Pharmaceuticals, Inc. and Blueprint Medicines Corporation offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, starting at $40 million and reaching $80 million. In contrast, Blueprint Medicines saw a staggering increase of over 3,600%, from $7.9 million to nearly $295 million.
Amphastar's steady growth in SG&A expenses reflects a controlled expansion strategy, maintaining a consistent increase year-over-year. Meanwhile, Blueprint's exponential rise suggests aggressive scaling, likely driven by rapid R&D and market expansion. This divergence highlights the strategic choices companies face in balancing cost management with growth ambitions.
Understanding these trends offers valuable insights into how pharmaceutical companies navigate financial challenges in a dynamic market.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE